IP Library Granted Patent US 8,148,157
Granted Patent B2
US 8,148,157 · App. 12/349,695 · Granted Apr 3, 2012

Reference, calibrator, or control composition of PIGF-1 and sFlt-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,157
App. No.
12/349,695
Granted
Apr 3, 2012
Kind
B2
Abstract

Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.

Claims (12)

1. A reference, calibrator or control composition comprising PlGF-1 and sFlt-1, where the PlGF-1 comprises alanine in place of:

a) proline at position 25 of SEQ ID NO:1, or

b) glutamine at position 27 of SEQ ID NO:1, or

c) cysteine at position 60 of SEQ ID NO:1, or

d) aspartate at position 72 of SEQ ID NO:1 or

e) glutamate at position 73 of SEQ ID NO:1, or

f) asparagine at position 84 of SEQ ID NO:1, or

g) proline at position 98 of SEQ ID NO:1, or

h) tyrosine at position 100 of SEQ ID NO:1, or

altered PlGF-1 having glycine in place of cysteine at position 70 of SEQ ID NO:1, or any combination of the alanine replacements in a) to h) and the glycine replacement.

2. The composition of claim 1 wherein PlGF-1 comprises alanine in place of aspartate at position 72 of SEQ ID NO:1 and alanine in place of glutamate at position 73 of SEQ ID NO:1.

3. The composition of claim 1 wherein PlGF-1 comprises glycine in place of cysteine at position 70 of SEQ ID NO:1, alanine in place of aspartate at position 72 of SEQ ID NO:1 and alanine in place of glutamate at position 73 of SEQ ID NO:1.

Assignments (5)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
Reel/Frame 060219/0571 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
SECURITY INTEREST Recorded Jul 3, 2014
From: ORTHO-CLINICAL DIAGNOSTICS, INC; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 033276/0104 →